The down‐regulation of Bcl‐2 and up‐regulation of Bax following bortezomib treatment indicate that the apoptotic process was activated in the treated glioma cells, thus mediating an anti‐tumour effect, and inhibition of PLK4 further enhanced this effect. Here, BCL2 is linked to central nervous system cancer.